CSL (ASX:CSL) share price dips amid $10b acquisition rumours

The biotech giant's share price finished in the red on Thursday.

Shares in global biotech giant CSL Limited (ASX: CSL) edged lower today and finished more than 1% in the red at $305.23.

CSL held the fort across the day, with intraday prices trading in a narrow spread of $307–$308 before a large set of trades sent its share price as low as $301.11.

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

Acquisition rumours?

Rumours are circulating that the Aussie biotech is set to buy Vifor Pharma, a Swiss-based company, in a deal that could see CSL fork out $10 billion.

According to reporting from The Australian, CSL might be heading to the capital markets to raise additional equity capital to the tune of $3 billion–$4 billion.

Both CSL and Vifor have been in a game of verbal ping-pong with talks of the acquisition first circulating back in March this year. If the deal goes through, it would mark the CSL's first major acquisition in over 10 years.

It is understood that Bank of America and Goldman Sachs are to be involved with the transaction, and both banks will nab a hefty fee from CSL's capital raise if it is successful.

Vifor states that it aims to be a leader in iron deficiency, nephrology and cardio-renal therapies, with a focus on chronic disease.

It recognised 1.7 billion Swiss Francs in revenue in 2020 and has a market cap of 6.75 billion Swiss Francs ($10.33 billion). For comparison, CSL's market cap is $140.88 billion.

Vifor itself has been busy on the acquisition trail as well, recently confirming it bought 100% of cardio-renal biopharma company, Sanifit Therapeutics on 22 November.

Curiously, former CSL non-executive director, Abbas Hussain – who resigned from CSL's board in June this year – was recently appointed as the new CEO of Vifor Pharma.

Hussain joined the company on 16 August and will hold tenure as Vifor's top executive after serving on CSL's board for 4 years.

Without further clarification from CSL itself, it is unwise to make any speculation on the matter. However, CSL is well capitalised with over $8.3 billion in net assets – of which $1.8 billion is in cash on the balance sheet.

CSL share price snapshot

The CSL share price has climbed almost 1% in the past 12 months and almost 8% this year to date.

In the past week, it has slipped almost 4% but is in the green by 2% in the past month.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »